Targovax to present at NeoAg Summit 2018
Oslo, Norway, 16 November 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that CMO Magnus Jäderberg will present at the NeoAg Summit 2018 (formerly Neoantigen Summit) in Boston NeoAg Summit 2018Date: 16 November 2018Presenter: Dr. Magnus Jäderberg, CMOPresentation time: 11:00 ETVenue: Hyatt Regency Cambridge, Boston. Title: TG01, a neo-antigen specific vaccine targeting RAS mutations in solid tumours Presentation slides will be available on www.targovax.com/Investors.